These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23824468)

  • 21. [Present and future of trial design].
    Vargas Vorácková F
    Rev Invest Clin; 1990 Jul; 42 Suppl():36-8. PubMed ID: 19256131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Temporal bias in case-control design: preventing reliable predictions of the future.
    Yuan W; Beaulieu-Jones BK; Yu KH; Lipnick SL; Palmer N; Loscalzo J; Cai T; Kohane IS
    Nat Commun; 2021 Feb; 12(1):1107. PubMed ID: 33597541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The futility index. An approach to the cost-effective termination of randomized clinical trials.
    Ware JH; Muller JE; Braunwald E
    Am J Med; 1985 Apr; 78(4):635-43. PubMed ID: 3920906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2).
    Briel M; Lane M; Montori VM; Bassler D; Glasziou P; Malaga G; Akl EA; Ferreira-Gonzalez I; Alonso-Coello P; Urrutia G; Kunz R; Culebro CR; da Silva SA; Flynn DN; Elamin MB; Strahm B; Murad MH; Djulbegovic B; Adhikari NK; Mills EJ; Gwadry-Sridhar F; Kirpalani H; Soares HP; Abu Elnour NO; You JJ; Karanicolas PJ; Bucher HC; Lampropulos JF; Nordmann AJ; Burns KE; Mulla SM; Raatz H; Sood A; Kaur J; Bankhead CR; Mullan RJ; Nerenberg KA; Vandvik PO; Coto-Yglesias F; Schünemann H; Tuche F; Chrispim PP; Cook DJ; Lutz K; Ribic CM; Vale N; Erwin PJ; Perera R; Zhou Q; Heels-Ansdell D; Ramsay T; Walter SD; Guyatt GH
    Trials; 2009 Jul; 10():49. PubMed ID: 19580665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The past is the future: innovative designs in acute stroke therapy trials.
    Krams M; Lees KR; Berry DA
    Stroke; 2005 Jun; 36(6):1341-7. PubMed ID: 15879340
    [No Abstract]   [Full Text] [Related]  

  • 26. Quality and reporting of trial design in scientific papers in Anaesthesia over 25 years.
    Langford RA; Huang GH; Leslie K
    Anaesthesia; 2009 Jan; 64(1):60-4. PubMed ID: 19032695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus.
    Reed SD; Anstrom KJ; Bakhai A; Briggs AH; Califf RM; Cohen DJ; Drummond MF; Glick HA; Gnanasakthy A; Hlatky MA; O'Brien BJ; Torti FM; Tsiatis AA; Willan AR; Mark DB; Schulman KA
    Am Heart J; 2005 Mar; 149(3):434-43. PubMed ID: 15864231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bayesian statistical method was underused despite its advantages in the assessment of implantable medical devices.
    Pibouleau L; Chevret S
    J Clin Epidemiol; 2011 Mar; 64(3):270-9. PubMed ID: 20800443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two-Stage Single-Arm Trials Are Rarely Analyzed Effectively or Reported Adequately.
    Grayling MJ; Mander AP
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34950839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bayesian approach to noninferiority trials for proportions.
    Gamalo MA; Wu R; Tiwari RC
    J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop.
    Coffey CS; Levin B; Clark C; Timmerman C; Wittes J; Gilbert P; Harris S
    Clin Trials; 2012 Dec; 9(6):671-80. PubMed ID: 23250942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The value in cancer care consortium: addressing financial toxicity.
    Lichter AS
    Clin Adv Hematol Oncol; 2017 Sep; 15(9):680-681. PubMed ID: 28949938
    [No Abstract]   [Full Text] [Related]  

  • 33. Bayesian estimation of cost-effectiveness from censored data.
    Heitjan DF; Kim CY; Li H
    Stat Med; 2004 Apr; 23(8):1297-309. PubMed ID: 15083484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bayesian estimation of cost-effectiveness: an importance-sampling approach.
    Heitjan DF; Li H
    Health Econ; 2004 Feb; 13(2):191-8. PubMed ID: 14737756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bias in transfusion research: from study design to result reporting.
    Arnold DM
    Transfusion; 2011 Feb; 51(2):237-40. PubMed ID: 21309776
    [No Abstract]   [Full Text] [Related]  

  • 36. Lessons learned from recent cardiovascular clinical trials: Part II.
    DeMets DL; Califf RM
    Circulation; 2002 Aug; 106(7):880-6. PubMed ID: 12176964
    [No Abstract]   [Full Text] [Related]  

  • 37. Conditional estimation using prior information in 2-stage group sequential designs assuming asymptotic normality when the trial terminated early.
    Shimura M; Maruo K; Gosho M
    Pharm Stat; 2018 Sep; 17(5):400-413. PubMed ID: 29687592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 3: Design considerations.
    Ball G; Silverman MH
    Contemp Clin Trials; 2011 Sep; 32 Suppl 1():S8-10. PubMed ID: 21664988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bayesian design of noninferiority trials for medical devices using historical data.
    Chen MH; Ibrahim JG; Lam P; Yu A; Zhang Y
    Biometrics; 2011 Sep; 67(3):1163-70. PubMed ID: 21361889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomised trials with provision for early stopping for benefit (or harm): The impact on the estimated treatment effect.
    Walter SD; Guyatt GH; Bassler D; Briel M; Ramsay T; Han HD
    Stat Med; 2019 Jun; 38(14):2524-2543. PubMed ID: 30887553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.